drugset / Trial / NCT01018875

Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease

NCT01018875

Phase 2 Completed 242 enrolled AbbVie
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Efficacy and safety study of ABT-288 in adults with mild-to-moderate Alzheimer's disease.

Timeline

Start
2009-12
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject ABT-288 Small molecule
Comparator Donepezil Small molecule

Indications